Announced Date: 2023-11-09 (November 9, 2023) Asset Name: ECC5004（AZD5004） Licensor: Eccogene (China) Licensee (Buyer): AstraZeneca（UK） . … [China BD 2023] Eccogene and AstraZeneca enters a 2 billion USD license on GLP-1RA ECC5004 (AZD5004)Read more
[China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
Announced Date: 2023-11-06 (November 6, 2023) Asset Name: PM8002 (BNT327) Licensor (Seller): Zhuhai Biotheus Inc (China) … [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)Read more
[China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)
Announced Date: 2023-10-12 (October 12, 2023) Asset Name: YL202 (BNT326) Licensor (Seller): MediLink Therapeutics (China) Licensee … [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)Read more
[China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089
Announced Date: 2023-10-20 (October 20, 2023) Asset Name: HS-20089 Licensor: Hansoh Pharma (Hansoh) (China) Licensee (Buyer): … [China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089Read more
[China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091
Announced Date: 2023-09-12 (September 12, 2023) Asset Name: ISM3091 Licensor: InSilico Medicine (China) Licensee (Buyer): Exelixis, … [China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091Read more
[China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305
Announced Date: 2023-05-12 (May 12, 2023) Asset Name: LM-299 Licensor (Seller): LaNova Medicines (LaNova) (China) Licensee … [China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305Read more
[China BD 2023] Zion Pharma and Roche enters a 680 million USD acquisition on HER2 TKI ZN-A-1041 (RG6596)
Announced Date: 2023-05-09 (May 9, 2023) Asset Name: ZN-A-1041 (RG6596, perzebertinib) Licensor (Seller): Zion Pharma (China) … [China BD 2023] Zion Pharma and Roche enters a 680 million USD acquisition on HER2 TKI ZN-A-1041 (RG6596)Read more
[China BD 2023] DualityBio and BioNTech enters a 1.67 billion USD license on two ADC Assets, HER2 ADC DB-1303 (BNT323) and B7-H3 ADC DB-1311 (BNT324)
Announced Date: 2023-04-03 (April 3, 2023) Asset Name: DB-1303(BNT323)，DB-1311(BNT324) Licensor: Duality Biologics (Suzhou) (DualityBio, China) Licensee … [China BD 2023] DualityBio and BioNTech enters a 1.67 billion USD license on two ADC Assets, HER2 ADC DB-1303 (BNT323) and B7-H3 ADC DB-1311 (BNT324)Read more
[China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2/JAK1 Inhibitor TLL-041 (BHV-8000)
Announced Date: 2023-03-22 March 22, 2023) Asset Name: TLL-041 (BHV-8000) Licensor (Seller): Hangzhou Highlightll Pharmaceutica (China) … [China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2/JAK1 Inhibitor TLL-041 (BHV-8000)Read more
[China BD 2023] KYM Biosciences (Keymed / Lepu) and AstraZeneca Enters License on Claudin-18.2 ADC CMG901
Announced Date: 2023-02-23 (February 23, 2023) Asset Name: CMG901 Licensor (Seller): KYM Biosciences (China) (joint venture … [China BD 2023] KYM Biosciences (Keymed / Lepu) and AstraZeneca Enters License on Claudin-18.2 ADC CMG901Read more